Replies to post #16201 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

By sell-off I did mean to re-partner. Momenta would be doomed if it tried to take it to market alone.

I'd guess they'd partner with someone who's in the doc's office already who doesn't have to add a sales force.

[jbog]

Momenta, AbbVie analyst commentary at Maxim

Question on Momenta's biosimilar Humira not efficacy, but legality, says Maxim.

Maxim analyst Jason McCarthy noted that Momenta (MNTA) announced that M923, its biosimilar version of Humira, met the primary endpoint in a trial of its efficacy, but added that the question about the product "is not efficacy, it is legal." If M923 is approved, a fight over IP with AbbVie (ABBV) could delay the commercial launch to 2022 or later, said McCarthy, who keeps a Sell rating on Momenta shares.


Read more at: http://thefly.com/landingPageNews.php?id=2469383